Steve,
As I've said before, GLFD has an interesting neuroscience program, and when they went public, it was about the only company around that was working on neurotrophic drugs. Indeed, my interest in this stock has been based largely on that program. While they may have the best program (I am not enough of a biologist to know), it ain't the fastest. Since going public, GLFD has yet to get such a drug in trials. Meanwhile, the competition in this area is passing GLFD by. I think one American big Pharma has such a program, an Austrian company whose name escapes me is headed for trials, and NEOT has completed PII trials for Alzheimer's with good results.
biz.yahoo.com
So despite the insider buying, I think the stock is near its lows for a reason. Apparently, Amgen has some control over the pace of the program. Whether it is Amgen or GLFD that is being slow doesn't matter much, though. The point is, the process is too slow.
GLFD finally got funding for their cocaine addiction candidate, and they are now building the lab. This is another interesting program, the more so because the technique might apply to other addictions such as alchoholism. It is also one in which they have less competition (I am not aware of any), but it is still years from producing anything.
GLFD may one day shine, but it'll be while -- as in several years -- IMO, and at best will be dead money for a while.
Cheers, Tuck |
